Trial
NCT04743804
Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
Thrombotic Microangiopathy
Intervention
Ravulizumab
Why stopped
Recruitment Challenges
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-01